Orchestration of signaling by structural disorder in class 1 cytokine receptors by Seiffert, Pernille et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Orchestration of signaling by structural disorder in class 1 cytokine receptors
Seiffert, Pernille; Bugge, Katrine; Nygaard, Mads; Haxholm, Gitte W.; Martinsen, Jacob H.;
Pedersen, Martin N.; Arleth, Lise; Boomsma, Wouter; Kragelund, Birthe B.
Published in:
Cell Communication and Signaling
DOI:
10.1186/s12964-020-00626-6
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Seiffert, P., Bugge, K., Nygaard, M., Haxholm, G. W., Martinsen, J. H., Pedersen, M. N., ... Kragelund, B. B.
(2020). Orchestration of signaling by structural disorder in class 1 cytokine receptors. Cell Communication and
Signaling, 18(1), [132]. https://doi.org/10.1186/s12964-020-00626-6
Download date: 09. Oct. 2020
RESEARCH Open Access
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disorder in class 1 cytokine receptors
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Abstract
Background: Class 1 cytokine receptors (C1CRs) are single-pass transmembrane proteins responsible for
transmitting signals between the outside and the inside of cells. Remarkably, they orchestrate key biological
processes such as proliferation, differentiation, immunity and growth through long disordered intracellular domains
(ICDs), but without having intrinsic kinase activity. Despite these key roles, their characteristics remain rudimentarily
understood.
Methods: The current paper asks the question of why disorder has evolved to govern signaling of C1CRs by
reviewing the literature in combination with new sequence and biophysical analyses of chain properties across the
family.
Results: We uncover that the C1CR-ICDs are fully disordered and brimming with SLiMs. Many of these short linear
motifs (SLiMs) are overlapping, jointly signifying a complex regulation of interactions, including network rewiring by
isoforms. The C1CR-ICDs have unique properties that distinguish them from most IDPs and we forward the
perception that the C1CR-ICDs are far from simple strings with constitutively bound kinases. Rather, they carry both
organizational and operational features left uncovered within their disorder, including mechanisms and
complexities of regulatory functions.
Conclusions: Critically, the understanding of the fascinating ability of these long, completely disordered chains to
orchestrate complex cellular signaling pathways is still in its infancy, and we urge a perceptional shift away from
the current simplistic view towards uncovering their full functionalities and potential.
Keywords: IDRs, IDPs, Signaling, NMR, SAXS, SLiM, Disorder, Structural biology, CIDER, IDDomainSpotter, Cytokine
receptors, Transmembrane receptors
Background
The sequencing of the human genome and key observa-
tions from earlier research [1, 2], spurred the recognition
of proteins and protein regions functioning without hav-
ing three-dimensional folds. These intrinsically
disordered proteins (IDPs) and regions (IDRs, collect-
ively here referred to as IDPs), constitute around 30–
40% of the human proteome [3] and perform key cellu-
lar and highly regulated processes such as transcription,
translation and signaling [4–7]. IDPs show distinct se-
quence characteristics with higher frequencies of Pro,
Glu, Ser, Gln, Lys, Ala, and Gly, and lower frequencies
of Val, Leu, Ile, Trp and Cys. Hence, their sequences
have particular properties of low hydrophobicity and
high charge [8], resulting in their intrinsic inability to
fold into a single, well-defined structure. Instead, IDPs
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take on ensembles of almost isoenergetic states, although
these are far from random. For example, they may har-
bor lowly populated secondary structures that are rele-
vant to binding [9] and to tuning the disordered
ensemble [10], and alteration in the populations of these
elements by e.g. mutations may lead to promotion of
pathological states [11]. Interactions by IDPs are often
mediated by short linear motifs (SLiMs), which are 2–12
residue sequence stretches that are typically recognized
by patterns of conserved residues within an otherwise
sparsely conserved sequence stretch [12]. SLiMs may
overlap, and due to the structural plasticity of disordered
regions, transiently exposed motifs and binding inter-
faces thus provide a trait of multispecificity to an other-
wise simple binding site. Furthermore, flanking residues
outside a SLiM and post translational modifications
(PTMs) can tune affinity and add regulatory properties
assisting in the spatiotemporal orchestration of multiple
binding events [13, 14]. Indeed, PTMs are frequent in
IDPs, in particular phosphorylations [15] and ubiquityla-
tion [16], impacting functionalities and regulatory poten-
tial in several different ways. Thus, PTMs allow IDPs to
function in rheostatic regulation [17] which are graded
quantitative responses, and may also drive the formation
or disruption of membrane-less organelles through pro-
cesses known as liquid-liquid phase separation (LLPS)
[18, 19]. Finally, the disordered nature of IDPs allows
them to exploit diverse binding mechanisms by which
they can fold-upon-binding [20–22], but also form com-
plexes in which structural disorder is maintained to dif-
ferent degrees [23]. Here, the most extreme case is the
formation of a completely disordered complex of func-
tional relevance and extreme affinity [24].
The class 1 cytokine receptors
Structural disorder also exists in membrane proteins
[25]. Besides being located in longer, disordered loops
connecting transmembrane helices, such as in the
sodium proton exchangers [26] and β1-adrenergic
receptor [27], disorder prevails preferentially on the
intracellular side [28], with membrane proteins having
disordered N- and C-terminal tails of various length
[29]. In fact, ~ 10% of the human membranome have
disordered intracellular domains of > 100 residues classi-
fying them as long disordered regions [29] and ~ 40%
have disordered domains of > 30 residues [28]. For the
subgroup of single-pass membrane proteins, an analysis of
> 350 human sequences found disorder to be concen-
trated in the cytoplasmic domains [30], confirmed in very
early work on gliotactin, a single-pass transmembrane
receptor involved in cell adhesion [31]. An important
family of single-pass transmembrane proteins with long
disordered tails is the class 1 cytokine receptors (C1CRs)
[32–34]. This family constitutes 40 members, which have
been divided into five different groups based on their
structural properties [33]. They all share having a tripartite
structure characterized by a folded, extracellular domain
(ECD) of various sizes and complexities, a single trans-
membrane helix (TMD), and an intracellular domain
(ICD), also of varying length. Recently, the proportions of
the different domains were exemplified by the a three-
dimensional structural model of the prolactin receptor
(PRLR); the first full-length structure of any cytokine re-
ceptor [35], Fig. 1a. C1CRs are characterized by the pres-
ence of two conserved cysteine bridges in the membrane
distal fibronectin type III domain (D1) of the ECD, a
WSxWS motif in the membrane proximal domain (D2) of
the ECD, and two conserved sequence motifs in their
ICD, Box1 and Box2 [32, 36]. The modular structures of
the ECDs of the 40 receptors are well known and de-
scribed broadly (see e.g. [32, 33]). Of the 40 receptors,
29 have an ICD (Fig. 1c), which all lack globular domains
and intrinsic kinase activity. Signaling therefore critically
depends on associated kinases such as Janus kinase 1–3
(JAK1, JAK2, JAK3) and tyrosine kinase 2 (TYK2) [37],
Src kinases and mitogen activated protein kinases
(MAPKs) [38]. Box1 is a proline-rich SLiM, onto which
JAK are proposed to be constitutively bound [39–41].
Box2 is a less conserved region consisting of a sequence of
hydrophobic residues, followed by negatively and then
positively charged residues [42, 43]. The function of
Box2 is unclear, but it is suggested to be important for
efficient binding and activation of JAK1/2/3 and TYK2,
possibly in cooperation with the region between Box1
and Box2 [39]. Recently, structures of complexes be-
tween JAK1/2 and TYK2 and a fragment of a cytokine
receptor ICD were solved, namely of the erythropoietin
receptor (EPOR) [44] (Fig. 1b), and of two class II cyto-
kine receptors ICDs from the interferon-λ receptor 1
(IFNLR1) [45] and interferon-α receptor chain 1 (IFNA
R-1) [46], respectively. These complexes have revealed
a common mode of interaction, where Box1 makes
hydrophobic contacts to the FERM-domain of JAK1/2;
TYK2 and a Glu of Box2 intercalates into the phospho-
tyrosine binding pocket of the non-canonical SH2 do-
main of JAK1/2;TYK2, Fig. 1b. Src kinases are also sug-
gested to bind to this region [47–50] most likely via a
SH3-SH2 interaction.
C1CRs act in homo- and heteromeric dimers and olig-
omers, in some of which they share common receptor
chains (IL-6Rβ (gp130), βc (IL-3Rβ) and γc (IL-2Rγ)). By
binding the cytokine on the extracellular side, multiple
common and receptor specific signaling events are initi-
ated intracellularly with the main common pathways be-
ing activation of JAK/STAT, Src and MAPK signaling
(for reviews on signaling, see e.g. [37, 38]). The receptors
of the homodimeric group 1 (sometimes referred to as
Type 1), constituting the EPOR, the growth hormone
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Fig. 1 The C1CR family - structures and ICD isoforms. a Structural model of the full-length human PRLR [35] in the membrane, with the ECD in
light grey, the TMD in pink and a total of six ICD chains shown in blue shades to represent its disordered conformational ensemble. b Left: A
representative sketch of a prototypical C1CR (blue) in a membrane (green) having a long ICD with its length given in %. Box1 and Box2 are
highlighted in orange. The red shades highlight the approximate extent and position of small ICD fragments of different C1CR-ICDs having their
structure solved in complex with signaling proteins. Right: Three-dimensional structures of signaling proteins (grey surfaces) in complex with
C1CR-ICD fragments (red cartoon and sticks), being the FERM-SH2 domain of JAK2 in complex with EPOR-ICD279–334 (pdb code 6E2Q) (top),
SOCS2 in complex with GHR-ICD591–603 (pdb code 6I5J, 6I5N) (middle top), the PTB domain of IRS-1 in complex with IL-4Rα490–500 (pdb code
1IRS) (middle bottom) and the PDZ domain from syntenin in complex with IL-5Rα417–420 (pdb code 1OBZ) (bottom). The grey arrows point to the
approximate positions of the ICD fragments (red shades) on the representative ICD sketch. c The 29 receptors of the C1CR family with an ICD
and their isoforms. The length of the ICDs are to scale and red indicates the length of unique sequences differing from the long-form. The
receptors are divided into 5 groups according to [33].
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receptor (GHR), the thrombopoietin receptor (TPOR)
and the PRLR, are considered to be structurally the sim-
plest. This group has served as paradigmatic models of
the family, and studies on the GHR have suggested that
hormone binding leads to conformational changes in the
receptor, including realignment and separation of the
lower transmembrane domains, ultimately resulting in
trans-phosphorylation of JAK2 and phosphorylation of
the ICDs to initiate signaling [51, 52].
Isoforms of C1CRs
Alternative splicing has been suggested to fine-tune the
functions of IDPs [53, 54] and in accordance with this,
functionally relevant alternative splicing has been shown
to occur primarily in IDPs [53–56]. Furthermore, a
large-scale computational analysis of alternative exons in
human genes showed that alternatively spliced IDPs
were highly enriched in interaction sites and regions
modified by PTMs [53]. This has been suggested to pro-
vide a mechanism to rewire interaction networks by in-
cluding or eliminating specific interaction motifs or
binding sites [54]. Alternative splicing is further sug-
gested to be important for maintaining tissue identity, as
tissue-specific exons were shown to contain disordered
regions enriched in PTMs and binding motifs that were
central parts of tissue-specific interaction networks [53].
Many of the C1CRs also exist in different isoforms, but
there are currently no reports available on their proper-
ties or numbers, or how their characteristics differ. For
the PRLR, there are to date nine isoforms identified in
humans, with four differing in their ECD [57–60], out of
which one is an ECD soluble isoform [61]. The
remaining five isoforms result from alternative mRNA
splicing, and differ solely in length and amino acid com-
position of the ICD. These ICD isoforms constitute the
predominant long form (LF, 622 residues), the inter-
mediate form (IF, 349 residues), the short form 1a (SF1a,
376 residues), the short form 1b (SF1b, 288 residues)
and the short form 1c (SF-1c, 309 residues), Fig. 1c.
Compared to the LF, the IF, SF1a, SF1b and SF1c con-
tain 13, 39, 3 and 24 unique C-terminal residues, re-
spectively. The LF, IF, and SF1a all contain Box1 and
Box2 motifs, while SF1b only contains Box1 [62–64].
Since activation of the JAK2/STAT5 pathway requires
C-terminal tyrosine phosphorylation in the PRLR-ICD
[65], this pathway is only activated by the LF due to lack
of pYxxQ docking site motifs in the others [62, 64, 66,
67]. In contrast, the MAPK pathway is activated by the
LF, SF1a, and SF1b [66, 68, 69], while the PI3K pathway
is activated by both the LF [70, 71] as well as the short
isoform in mice [66]. Heterodimerization of the LF with
either of the shorter isoforms has been shown to inhibit
activation of the JAK2/STAT5 pathway [62, 63]. The
shortest isoform, PRLR-SF1b, has been shown to
negatively regulate PRLR signaling [65]. Hence, isoform
ratios need to be delicately balanced, and an increased
ratio of short- to long forms has implications in breast-
[72] and prostate [73] cancers. Lastly, since the different
PRLR isoforms are expressed to different extents in dif-
ferent cell types and under different conditions [62–64],
alternative splicing adds layers of regulation to PRLR
signaling.
Structural biology of C1CRs
Many C1CRs have been subjected to structural investi-
gations, but remarkably, > 95% of the available structural
information comes from the ECDs alone or in com-
plexes with cytokine ligands. Furthermore, most ECD
structures have been solved by X-ray crystallography,
not providing information on dynamical parts. The un-
derstanding of the structure and function of single-pass
TMDs is generally lacking behind [74]. For the C1CRs,
structures of the TMDs have been solved almost exclu-
sively on group 1 members, i.e. PRLR [35], EPOR [75,
76] and GHR [77] using detergent solubilized peptides
and nuclear magnetic resonance (NMR) spectroscopy in
both monomeric and dimeric states. However, mono-
meric structures have also been solved of the common
receptor βc in bicelle membrane mimetics [78]. Still, no
structural information is available for almost one fourth
of the receptors, including the TPOR, interleukin (IL)-
31Rβ, IL-31Rα, IL-12Rβ1, IL-12Rβ2, IL-27R, IL-9Rα, IL-
11Rα, and the oncostatin-M-specific receptor (OSMR).
Furthermore, only six structures are available of shorter
fragments of ICDs in complex with signaling molecules,
as exemplified by the juxtamembrane domain of the
EPOR in complex with the FERM-SH2 domains of JAK2
[44], a 12-residue phospho-peptide from GHR-ICD in
complex with SOCS2 [79], an 11-residue phospho-
peptide of IL-4R-ICD with the phospho-tyrosine binding
domain of the insulin receptor substrate (IRS)-1 [80],
and an 8-residue peptide from IL-5Rα-ICD with the
PDZ domain of syntenin [81], Fig. 1b. Drawn to scale on
a representative ICD model (Fig. 1b), these binding sites
take up only a minor part of the ICD, and leave a large
area completely unexplored; not to mention the > 25 re-
ceptors for which no structures of any part of the ICD
are available.
Using a combination of small-angle X-ray scattering
(SAXS), NMR and circular dichroism (CD) spectroscopy
we recently performed an extensive characterization of
the ICD of GHR and PRLR, showing that the entire
ICDs of the LFs of the human PRLR (PRLR-LF-ICD)
and the human GHR (GHR-LF-ICD) are disordered,
with only transiently populated helices [35, 82]. More-
over, the PRLR-LF-ICD interacts specifically with hall-
mark lipids of the inner membrane leaflet through three
lipid interaction domains (LIDs), one overlapping with
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Box1 and Box2. The most membrane proximal of these
was also identified in the GHR-LF-ICD suggesting simi-
lar roles in signaling. The only other reports on struc-
tural characterization of unbound ICDs of cytokine
receptors available in the literature are on small syn-
thetic peptides. One example is a 17-residue peptide
from the IL-2Rβ-ICD covering a sorting signal
(P285SKFFSQL292) and forming a type I β-turn [83]. An-
other example is a short peptide from PRLR-ICD con-
taining the Box1 sequence (I243FPPVPGP250). The latter
work suggested the presence of cis-trans isomerization
of Pro248, the third proline of Box1 [84], supported by a
suggested interaction with cyclophilin A (CypA), which
co-immunoprecipitated with the first 76 intracellular
residues of PRLR [85]. Besides for EPOR, PRLR and
GHR, and the short 5–10 residue peptides from the IL-
4R and IL-5Rα, the ICDs of the remaining 26 C1CRs of
the family have not been studied at the atomic level, and
only the PRLR-ICD and GHR-ICD have been studied in
complete forms. This leaves a critical knowledge void
inhibiting the understating of how C1CRs signal.
The present paper sets focus on the ICDs of the
C1CRs and their structural disorder, and asks why dis-
order has evolved to manage versatility and fidelity in
their signaling. We predict disorder in all human C1CRs
and list all known isoforms that differ in the ICD. We
analyze their primary structures, globally and locally,
and, sequentially and experimentally analyze chain be-
havior identifying shared and unique characteristics
across the family. We show that their sequences are
brimming with SLiMs, conferring multispecificity to the
chains. Instead of considering the ICDs as passive scaf-
folds for kinases, we put forward a more complex view
of active orchestration via organizational and operational
features left uncovered within their disorder.
Materials and methods
Proteins - expression and purification
Human PRLR-ICD236–396 was prepared as described in
[82]. PRLR-SF1b-ICD was produced as a GST-tagged fu-
sion protein containing a thrombin cleavage site. PRLR-
SF1b-ICD was purified essentially following the proced-
ure for PRLR-LF-ICD [82] with the following modifica-
tions: After inoculation of cells from overnight cultures
in LB-medium, cells were left growing at 37 °C until
OD600 = 0.8. The cells were subsequently centrifuged
gently for 15 min at 2500 x g at 4 °C, the supernatant
discarded, and the cells gently resuspended by swirling
in 500 mL 15N- or 13C- and 15N-labeled M9-minimal
media (1.5 g KH2PO4, 3.75 g Na2HPO4•2H2O, 0.5 g
NaCl, 1 mM MgSO4, 0.5 ml M2 trace solution, 2 g
13C
α-D-Glucose, 0.5 g 15NH4Cl) with 100 μg/ml Amp. The
cell suspension was transferred back into the 5 L Erlen-
meyer flask and left growing at 37 °C for 45 min after
which protein expression was induced with 1 mM iso-
propyl β-D-1-thiogalactopyranoside (IPTG) for 3 h. The
cells were harvested by centrifugation (20 min, 5000 x g,
4 °C) and stored at - 20 °C until thawed on ice and re-
suspended in 40 mL sonication buffer; 1x PBS (1.4 M
NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM KH2PO4,
10 x stock), 0.1% (v/v) Triton X-100 and one complete
EDTA-free protease inhibitor cocktail tablet (Roche
Diagnostics GmbH). The cells were sonicated on ice,
using an UP400S Ultrasonic Processor, 4 × 30 s with 30
s rest between rounds at 90% amplitude. The cell ex-
tracts were centrifuged (25 min, 20,000 x g, 4 °C), the
pellets discarded and the supernatants used for purifica-
tion. The glutathione column (Glutathione Sepharose 4
Fast Flow, GE Healthcare) was prepared by washing with
20 column volumes (CVs) 1xPBS buffer pH 8 and the
supernatant from sonication was incubated with the col-
umn material for 1 h at room temperature (RT) under
gentle agitation. The column was washed with 20 CVs
1xPBS buffer pH 8 and GST-PRLR-SF1b-ICD was eluted
using 10 CVs elution buffer (50 mM Tris-HCl pH 8, 10
mM reduced glutathione). The sample was dialyzed
overnight at 4 °C under stirring against 1 L thrombin
cleavage buffer (20 mM Tris-HCl, 150 mM NaCl pH
8.4) using a 6000–8000 MWCO dialysis membrane. One
hundred units of thrombin (GE Healthcare) was added
to the sample, which then incubated for 2 h at RT under
gentle agitation. After cleavage, the sample was concen-
trated using centrifugal filters (3000 MWCO, Millipore)
and applied to an analytical size exclusion column
(Superdex 75 10/300 GL, GE Healthcare) equilibrated
with 2 CVs of 50 mM Na2HPO4/NaH2PO4 pH 7.5, 150
mM NaCl and 0.1 mM DTT. The flowrate was 0.5 ml/
min and PRLR-SF1b-ICD was eluted over 1.5 CV GHR-
ICD-LF and PRLR-ICD-LF were preoduced as described
in [35, 82].
Lipids
Small unilamellar vesicles (SUVs) containing POPC/
POPS and POPC were prepared as in [82].
CD spectroscopy
Far-UV CD spectra were recorded on a Jasco-810 spec-
tropolarimeter from 250 nm to 190 nm with a scan
speed of 20 nm/min, bandwidth 1 nm, 2 s response time
at 25 °C in a 1 mm quartz cuvette. Protein concentration
was 19 μM in 10mM NaH2PO4-NaOH, pH 7.4, 1 mM
TCEP. The spectra were averaged over 10 scans with the
corresponding spectrum of the buffer subtracted. The
resulting spectra were smoothed using a fast Fourier
transform, removing the highest frequencies in the
spectrum.
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NMR spectroscopy
For backbone assignment, 13C-15N-labeled PRLR-SF1b-
ICD was concentrated to 500 μM in 20 mM Na2HPO4/
NaH2PO4 pH 7.3 or 7M urea pH 7.3 (native and dena-
tured conditions, respectively). The samples were added
10% (v/v) D2O, 5 mM tris (2-carboxyethyl) phosphine
(TCEP), and 0.5 mM 2,2-dimethyl-2-silapentane-5-sul-
fonic acid (DSS) for referencing in a total volume of
350 μl. The pH was adjusted to 7.3 if needed and the
samples were transferred to 5 mm Shigemi tubes. All
backbone spectra were recorded at 5 °C on Varian
INOVA 750- or 800-MHz (1H) spectrometers and back-
bone assignment accomplished from analyses of 1H-15N-
HSQC [86], HNCACB [87], CBCA (CO) NH [88], and
HNCO [89] spectra. Free induction decays were trans-
formed and visualized using NMRPipe [90] and analyzed
using CcpNmr Analysis [91]. Assignments were done
manually. Transient secondary structure elements were
identified by secondary chemical shifts (SCSs). These
were calculated by subtracting the Cα and C′ chemical
shifts for each residue in 7M urea from those obtained
in 20 mM Na2HPO4/NaH2PO4. The amount of transient
α-helices was assessed as described [92]. Two series of
1H-15N-HSQC [86] spectra were recorded on 15N-
PRLR-SF1b-ICD at 5 °C to analyze the relaxation times.
The spectra for PRLR-SF1b-ICD were recorded with
delay times of 10–1000 ms (T1) and 10–250 ms (T2)
with two triplicates in each series. The relaxation decays
were fitted to single exponentials and the relaxation
times were determined using the CcpNmr Analysis soft-
ware [91]. For CypA interaction studies, samples con-
taining 100 μM 15N-labelled PRLR-SF1b-ICD or PRLR-
LF-ICD with and without 85 μM human CypA (Sigma
Aldrich) were prepared in 20 mM Na2HPO4/NaH2PO4
pH 7.3, 10% (v/v) D2O, 1 mM TCEP, 0.5 mM DSS. To
accommodate slight differences in conditions of the dif-
ferent protein batches, all batches were thoroughly dia-
lyzed against the same buffer before mixing the samples.
1H-15N-HSQC spectra were recorded on each sample at
5 °C and chemical shift changes were analyzed as com-
bined amide chemical shift changes by δΔNH = ((δΔH)
2 +
(0.154*δΔN)
2)1/2 [93].
Small angle X-ray scattering
SAXS data were collected at the EMBL beamline P12 at
Petra III in Hamburg, Germany [94]. SAXS data on
PRLR-LF-ICD and GHR-LF-ICD (20 mM Na2HPO4/
NaH2PO4 (pH 7.3), 10 times molar excess DTT) were
collected at the PETRA III, P12 beamline (DESY syn-
chrotron, Hamburg), following standard procedures. A
series of different concentrations between 1 and 6mg/
mL were measured for each protein added 0, 75, 150
and 300 mM NaCl. The SAXS curves for PRLR-ICD-LF
and GHR-ICD-LF were analyzed using the form-factor
for a Gaussian random coil [95], together with a scaling
factor for correcting the protein concentration and a
constant to model the background. The fitting was done
with the minimize method in optimization library in the
scipy package for python 3 using the L-BFGS-B algo-
rithm. Uncertainties in the fitting parameters were esti-
mated from the diagonal of the inverse Hessian. Pair
distance distribution functions were calculated using the
BayesApp [96, 97] and using the GenApp server (https://
genapp.rocks (visited on April 15, 2020)). In the case of
PRLR-ICD-LF, a few data points were omitted at low-Q
based on the Guinier analysis, but data from 0.0075 Å-1
and up was used in all cases. The Guinier analysis was
also used to truncate the data for GHR-ICD so that only
data above 0.0084 Å-1 was used. Due to the lower S/N,
data above 0.3 Å-1 was also omitted from the analysis
and the Lagrange multiplier was fixed to 1014, in order
to ensure a stable solution with respect to data range
and input parameters.
To calculate a reference Rg for PRLR-LF-ICD and
GHR-LF-ICD, we used the power-law in Eq. 1, where R0
is a constant related to the persistence length of the
polymer, N is the number of amino acids and ν is related
to the nature of the polymer.
Rg ¼ R0Nν ð1Þ
For R0 and ν, we used the experimental parameters
from Kohn and co-workers [98], determined based on
chemically unfolded proteins, i.e. R0 = 1.927 Å and ν =
0.598, where the latter value is very close to the theoret-
ical value of 0.588 of self-avoiding polymer chains.
Disorder predictions, sequence alignments and
bioinformatics
The original list of C1CRs was manually curated from
the list of receptors in [33, 34], after which isoforms
were extracted from Uniprot [99]. Disorder predictions
for each of the sequences were conducted as described
previously [13], and the sequences were analyzed by
IDDomainSpotter [100], CIDER [101] and Weblogo3.0
[102] using standard setting and TMHMM was used to
predict borders between domains [103]. The amino acid
propensities for each of the sequences were calculated
relative to an ordered reference statistic, as (C(aa) - C_
ref(aa)) / C_ref(aa), where C(aa) is the frequency for the
individual residue and C_ref(aa) is the frequency of the
residue in the reference set. We calculated our ordered
reference frequencies, C_ref(aa), from entries in the
MobiDB database [104], using the curated DB set and
selecting all protein regions labeled as ‘S’. The same set
was used to calculate the frequencies for the Disorder
category in Fig. 2b, this time selecting regions labeled as
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Fig. 2 Intrinsic disorder and compositional bias of C1CR-ICDs. a Disorder prediction for C1CR common receptors and group 1. The disorder
propensity, ranging from 0 to 1 was predicted using IUPred2A (blue), ANCHOR (black) and Pondr-fit VSL2 (red) and is plotted as a function of
residue number. The boundaries between the ECD (white background), TMD (yellow background) and ICD (orange background) were predicted
using TMHMM v. 2.0. The sequence numbering includes the signal peptide. b Fractional differences in composition between the C1CR-ICDs (dark
grey) or a set of IDPs (light grey), and a set of folded proteins calculated for each amino acid type (see methods for details). Negative values
denote that the amino acid is less frequent than in folded proteins, and positive values denote that the amino acid is more frequent than in
folded proteins. The arrows indicate the directions of “more” abundant than in folded proteins, and “less” abundant than in folded proteins. The
error bars indicate the 90% confidence interval of the estimated frequencies, calculated using a per-protein bootstrapping procedure with 1000
iterations [105]. c IDDomainSpotter profiles of group 1 C1CR-ICDs. Profiles display scores for +Arg,Lys-Asp,Glu (green), +Cys (brown), +Pro (purple),
+ Ile,Leu,Val (red) and + Phe,Tyr,Gly (blue) calculated over 15 residue windows for each of the ICDs
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‘D’. To validate the sensitivity to this choice, we also cal-
culated the frequencies from the larger Derived MobiDB
set, with qualitatively similar results. Finally, we verified
the impact of homology reduction on these frequencies
by reweighting each protein by the number of other en-
tries in its UniRef50 class, but again observed similar re-
sults, and homology reduction was therefore omitted for
the remaining calculations. The error bars in Fig. 2b in-
dicate the 90% confidence interval of the estimated fre-
quencies, calculated using a per-protein bootstrapping
procedure with 1000 iterations [105].
SLiMs and phosphorylation sites were predicted in the
longest isoforms of group 1 receptors (PRLR-FL, GHR-
FL, EPOR-FL and TPOR1). SLiMs were predicted using
the ELM resource [106] and filtered based on taxonomic
context (Homo sapiens) and cellular compartment (cyto-
sol) with a probability cut-off of 100. Modification sites
were excluded from analysis. The iGPS 1.0 algorithm
[107] was used for prediction of in vivo phosphorylation
sites. Only instances above a medium threshold [107]
was included. Confirmed SliMs and phosphorylation
sites were manually curated.
Results and discussion
Disorder in C1CRs
The ICDs of the C1CRs have been very sparsely studied
structurally, likely because of their high expected abun-
dance of disorder. Moreover, many of the receptors exist
in several different alternatively spliced versions, some of
which differ in the ICDs. To provide an overview of the
ICD isoforms, we conducted a survey of known isoforms
of the entire family (Fig. 1c and Table 1). We followed
the grouping of the receptors made based on structure
and evolution [33, 34], but excluded receptors absent in
humans and/or for which no ICD could be annotated.
Furthermore, IL-2Rα and IL-15Rα were excluded as they
lack the structural hallmarks of the family and likely be-
long to a separate family [108]. This left us with a total
of 29 different receptors, distributed with four members
in group I (single-chain homodimers), ten members in
group II (the gp130 family, not counting receptors bind-
ing ancestral cytokines), two members in group III (sol-
uble α-chains, leaving out four receptors without ICDs
(IL-27Rβ, ciliary neurotrophic factor receptor subunit α
(cntfRα), cytokine receptor-like factor 1 (CRLF1), and
IL-12Rβ), six members in group IV (long-tailed receptor
chains) and seven members in group V (short-tailed re-
ceptor chains), Table 1. The 29 receptors provided a
total of 54 ICD isoforms distributed across all groups.
Approximately 40% of the receptors (12 receptors;
leukemia inhibitory factor receptor (LIFR), OSMR, IL-
6Rβ (gp130), IL-27R, IL-6Rα, IL-2Rβ, IL21R, IL4Rα, βc
(IL-3Rβ), CRLF2, γc (IL-2Rγ), IL-13Rα1, IL-13Rα2, and
IL3Rα) only had one ICD isoform, and three of these
were the common receptors IL-6Rβ (gp130), βc (IL-3Rβ)
and γc (IL-2Rγ). For the remaining 16 receptors, up to five
different isoforms could be identified and nine of the re-
ceptors with ICDs > 200 residues had a short isoform < 50
residues. A total of 16 isoforms had unique sequences,
typically > 10 residues with an average length of 25 ± 16
residues, and the longest unique sequence of 67 residues
belonged to the LEPR isoform C. The average length of
the longest ICD isoforms was 188 residues (group I), 210
residues (group 2), 82 residues (group 3), 335 residues
(group 4) and 65 residues (group 5) (Table 1). IL-4Rα had
the longest ICD of 575 residues (Table 1). Thus, the
C1CR-ICDs are generally long and some have isoforms
with unique sequences of considerable length.
The characteristic compositional bias of IDPs makes it
possible to predict the degree of disorder in proteins
computationally [109]. Almost 10 years ago, computa-
tional predictions of disorder was done for five of the
C1CRs [110], but disorder predictors have since im-
proved in quality and reproducibility [111], and no study
has examined the entire family in unison. We therefore
predicted the disorder profiles of the longest ICD iso-
forms of all 29 C1CRs as well as the propensity of re-
gions to undergo folding-upon-binding using the
ANCHOR scores [112] (Fig. 2a and SI Fig. S1). From
these predictions, we observed that the ICDs of the en-
tire family have high scores (> 0.5) for disorder along
their complete sequence and none were predicted to
harbor folded domains. Furthermore, almost all recep-
tors had lower disorder scores in the juxtamembrane
20–50 residues, a region overlapping with the JAK1/2/3;
TYK2 binding sites. Along the chains, regions of lower
disorder propensity were observed, which at the same
time were paralleled with high ANCHOR scores. Such
signatures suggest the region to be prone to folding-
upon-binding and thus constitutes a potential binding
site [112]. Indeed, the dip with the lowest disorder score
in PRLR-LF-ICD occurred around residue 610, which
corresponds to the region of tyrosine phosphorylation by
JAK2 (Y580/Y614), and docking site for STAT5 (YLDP).
Comparing the profiles across the group 1 C1CRs revealed
a similar pattern of disorder along the first 150–200
residues, although the extent of each of the regions with
higher/lower disorder vary (Fig. 2a). Similar group specific
profiles of some similarity in the first half of the ICDs
were seen for groups 2, 3, and 4, but not for group 5 (SI
Fig. S1); an observation likely reflecting their shorter ICDs.
Finally, we compared the disorder profiles for the five
different isoforms of the PRLR-ICD (SI Fig. S2). Despite
the change in sequence, all the ICD isoforms were
predicted to be disordered and with almost identical
disorder profiles. This is consistent with the general obser-
vation that sequence may change in a family of proteins
while the disorder-order profile persists [110, 113].
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In summary, the predicted disorder profiles support
that the ICDs of all the C1CRs are disordered (Fig. 2b)
and highlight common disorder profiles with a distribu-
tion of binding sites prone to folding-upon-binding.
The ICDs of the C1CRs have compositional biases
distinguishing them from other IDPs
To address if the C1CR-ICDs have physiochemical prop-
erties that distinguish them from other IDPs, we com-
pared the amino acid content of the entire family (Fig.
2b) as well as the individual groups (SI Fig. S3) to those
of folded proteins and other IDPs (for details see
methods). The analysis revealed that the C1CR-ICDs in-
deed have global sequence compositions that stand out
from other IDPs in three ways: First, some amino acids
are depleted in the C1CR-ICDs, namely Met, Arg, Ala
and Lys, which are less frequent than in general in IDPs
and in folded proteins. Second, Cys, Trp, Leu and Val
are significantly more frequent in the C1CR-ICDs than
in other IDPs, and are as frequent as in folded proteins
(except Val, which is less frequent than in folded pro-
teins). Third, Pro is highly enriched in the C1CR-ICDs,
and is even more frequent than in both folded proteins
and IDPs in general. These differences are remarkable,
but the role of these global compositional biases in
C1CR functionality remains to be understood. The de-
pletion in positively charged amino acids could be re-
lated to prevention of detrimental interactions with the
negatively charged inner membrane leaflet to which the
C1CR-ICDs are tethered through their TMDs, or with
other negatively charged molecules. The enriched Cys,
Trp, Leu, Val and Pro are in IDPs often found in SLiMs.
Indeed, the saturation of SLiMs along the C1CR-ICD
chains, as highlighted in Fig. 3 (see below), suggests en-
richment in binding sites and may reflect large interac-
tomes. Pro are known to preserve disorder in regions of
IDPs with residual structural propensities [115], and
hence could counter-balance the effects of the enrich-
ment in hydrophobic residues. Furthermore, the chemis-
try of Pro causes rigidification of the backbone and
consequently conformational expansion, as well as the
formation of polyPro type II (PPII) structures by Pro-
rich motifs [115]. Finally, several SLiMs and modifica-
tion sites are Pro-based, including binding sites for JAKs
and SH3s, and MAPK modification sites, which may in-
crease the relative content of Pro in C1CR-ICDs.
Thus, even though C1CR-ICDs are classified as disor-
dered from the disorder predictions, they have a remark-
able compositional bias that distinguishes them from
other IDPs, possibly due to SLiM enrichment.
Although sequence identity is often low among related
IDPs, the sequence characteristics important for func-
tion are typically conserved, whether it being specific
SLiMs, global conformational characteristics or specific
functional domains [100]. Thus, regions of specific resi-
due biases can be taken to represent domains of differ-
ent chemical and structural properties, which may
contribute differently to the function of the C1CR-ICDs.
To identify putative functional domains of specific
physio-chemical properties across the C1CR-ICDs we
submitted the sequences to IDDomainSpotter [100].
IDDomainSpotter reveals distinct conformational biases
in regions of long IDP sequences by calculating the frac-
tions of specified residues in a sliding window of 15 resi-
dues, meaning, that for each residue k, the fraction of
the specified residues between k-7 and and k + 7 is given.
Here, we have analyzed e.g. the charge composition by
setting Lys and Arg as positive contributions (+RK) and
Glu and Asp (−DE) as negative contributors (net
charge). Hence, a given residue k within the sliding win-
dow counts as + 1 if the position is a Lys or Arg, − 1 if
the position is Glu or Asp, and 0 for any other residue.
The IDDomainSpotter analysis of the C1CR-ICDs re-
vealed shared profiles for certain residues across the re-
ceptors (Fig. 2c), suggesting functional importance. First,
they all shared a region of 10–20 residues in the region
immediately following the TMD with a positive net
charge, as typically observed for type I membrane pro-
teins [30, 116]. This is followed by a region of ~ 50–60
residues (only ~ 20 residues for the shorter TPOR) with
a negative net charge (Fig. 2c, green). We denominate
these regions as the positive domain (PD) and the nega-
tive domain (ND), respectively. For the ICDs of PRLR
and GHR, the PD has been shown to specifically interact
with negatively charged lipids of the inner leaflet of the
membrane [82]. However, the role of the ND is not
understood. The negative charges may be relevant for
membrane repulsion, or for compaction with the PD
when not membrane bound. Alternatively, it could pro-
vide negatively charged flanking regions for specific
SLiMs, such as for Box2 binding to SH2 domains or
Pro-rich motifs binding to SH3 domains, as recently
supported by experiments [117]. Second, ~ 100 residues
and onwards from the TMD, the net charge was close to
equally balanced along the chains. Another shared prop-
erty is the almost equal distribution of the unusually
abundant Cys and Pro throughout the chains (Fig. 2c,
orange and purple). This could suggest that their abun-
dance is related to global conformational properties, ra-
ther than e.g. interaction sites or PPIIs. The ICDs of
group 1 further shared a pattern of depletion and en-
richment (20–50 residues) of the hydrophobic branched
amino acids Ile, Leu and Val throughout their chain
(Fig. 2c, red). Such hydrophobic side chains are usually
less abundant in IDPs because of the energetic penalty
of solvation, and hence in IDPs they are often primarily
located in e.g. SLiMs, or related to maintaining extended
β-structures of relevance to binding. Finally, clustering
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of Phe, Tyr and Gly (+FYG) was analyzed, as IDRs
enriched in these residues may be involved in liquid-
liquid phase separation [118, 119], but no major cluster-
ing of these were present throughout the chains.
The patterns observed for the group 1 receptors is
overall shared across the C1CR-ICDs, with the exception
of some noteworthy variations in charge composition.
Generally, all the C1CR-ICDs harbor a PD (sometimes
in a shorter version), followed by an ND of various
length, with subsequent close to net neutral charge along
the chains. However, the short ICDs of group 3 only
harbor a PD, and lack an ND. Furthermore, the ICDs of
IL-31Rβ (OSMR) (group 2) and IL-4Rα (group 4) lack
regions of substantial net charge throughout their ICDs,
including the PD; a trait that may be related to their as-
sociation with the IL-31Rα and IL-13Rα1, respectively.
Short linear motifs allow expansion of the interactome
In the disorder profiles and the IDDomainSpotter
analysis we observed distinct patterns, which may
suggest the presence of multiple binding sites [120]
(Fig. 2). For all receptors, the first region of low
Fig. 3 Short linear motifs form the basis for signaling choreography. a Sequence logo of the amino acid distribution in C1CR group 1 Box1 and Box2
motifs. Letter-height indicates the relative abundance of the given amino acid at the specific position. Red indicates an acidic residue, blue - a basic
residue, green – a polar residue, black – a hydrophobic residue and pink – a neutral residue [102]. b SLiM and phosphorylation site mapping in C1CR
group 1 ICDs. Regions with SLiMs are highlighted and colored according to the amount of overlap. Black indicates regions with no overlap. Yellow
indicates regions with two overlapping SLiMs, whereas red indicates regions with more than two overlapping SLiMs. Predicted phosphorylation sites
are indicated by grey diamonds [107] and confirmed and well-characterized sites by black diamonds. c Zoom on the membrane proximal 67-residue
region of GHR-LF-ICD containing overlapping binding sites. Box1 and Box2 are highlighted in blue. Proteins were illustrated in IBS 1.0.3 [114]
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disorder propensity corresponds to the juxtamem-
brane region containing the most conserved and well-
known motifs, Box1 and Box2, involved in JAK/TYK
binding. As a Pro-rich motif, Box1 represents one of
the most abundant SLiMs in the eukaryotic proteome
[121]. The polyPro scaffold inherently provides a con-
formational bias towards PPII formation [122], which
creates a structural predisposition that may drive an
interaction via reduced entropic penalty of complex
formation [123]. Except for group 5, which lacks ca-
nonical Box1 and Box2 motifs, all receptors harbor
the conserved PXP motif in Box1 (SI Fig. S4), known
to interact with the JAK-FERM domain [44, 124].
However, in most receptors, Box1 is further extended
to PXXPXP (consensus for group 1: φφPXφPXP,
where φ is any hydrophobic residue), which thereby
accommodates both the minimal SH3 binding motif
(PXXP) [125] and the FERM binding motif (PXP) in
one combined SLiM (Table 2). This enables competitive
binding to Src and JAK kinases [48, 126]. Although Box2
is remarkedly less conserved than Box1, sequence align-
ments reveal glutamates to be most abundant in Box2
(Fig. 3a). This is in accordance with their essential role as
phospho-mimics in binding to the atypical JAK-SH2 do-
main [44–46]. Studies suggest JAK kinase binding to be
driven by Box1 association to the FERM domain [45],
which thereby increases the local concentration of Box2
to the SH2 domains, further suggesting Box1 as the pri-
mary anchoring point.
In the membrane distal region, SLiMs constituting
docking sites for various signaling proteins have been
mapped experimentally. These SLiMs are predominantly
activated by phosphorylation to recruit SH2-containing
proteins, such as those in STAT and SOCS proteins
Table 2 Properties of disorder in C1CRs
IDP characteristic Key descriptors for C1CR ICDs
Specific amino acid
composition
The C1CR-ICDs have a unique amino acid composition that distinguishes them from both folded proteins and IDPs.
Depleted in Met, Arg, Ala, and Lys compared to folded proteins and IDPs Enriched in Cys, Trp, Leu and Val compared to
IDPs Highly enriched in Pro compared to folded proteins and IDPs
Disordered All the ICDs of the C1CRs are predicted disordered throughout their sequences, but has been shown experimentally
only for the GHR and PRLR
Rich in SLiMs #Several SLiMs are common to groups of the C1CRs, in particular
• BOX1 motifs (JAK/SH2)
ΦΦP.ΦP.P (JAK2) ΦP. P (JAK1)
ΦΦP.ΦP.[P/Φ].[P/Φ](JAK3/TYK2)
• 14–3-3
R[^DE](0,2)[^DEPG][ST][^PRIKGN]-P R[^DE](0,2)[^DEPG][ST][^P]*
• SOCS2/3
pY [AFILVWY].[AFILVWY] (loose SH2-motif)
• PDZ ..[ST].[ACVILF]* (Class 1)
..[VLIFY].[ACVILF]* (Class 2) ..[DE].[ACVILF]* (Class 3)
• TRAF2/6
[PSAT].[QE] E (TRAF2) [P].[Q]..D (TRAF2) [P].[Q]..[FYWHDE] (TRAF6)
• STAT
[Y]..[P] (STAT1)
[Y]..[Q] (STAT3) [Y][VLTFIC].. (STAT5) (promiscuous)
[Y]..[F] (STAT6)
• Phospho-degrons
D [S]G.(2,3[ST]
[LIVMP].(0,2)(T)P..[ST]
• Dileucine motifs
[D/E]...[L/I][L/I]
[D/E]..LL
• Tyrosine-based internalization motifs
Y..[LMVIF]
Only very few SLiMs have been addressed experimentally and only 7 three-dimensional structures exist of complexes.
Rich in PTMs All C1CR-ICDs have numerous predicted phosphorylation sites distributed along the chain, but only few have been con-
firmed by MS or by mutational studies. Some SLiMs are regulated by phosphorylation
Alternative splice variants Out of a total of 29 C1CRs, 16 have at least two isoforms differing in their ICDs, but up to five ICD isoforms are seen for
some receptors (PRLR, IL-31R).
Isoforms allow for network rewiring by insertion and deletion of specific SLiMs
Dynamic conformational
ensemble
The CIDER analysis and measured Rg of presentative C1CR-ICDs suggest that they take on a slightly compacted, but dy-
namic ensemble
Multispecificity Overlapping SLiMs dominates C1CR-ICDs and allow competition as a regulatory mechanism. This is made possible as
the disordered chain can adapts to several different binding partner.
#:^means that it cannot be a residue of this kind; * indicates the negatively charged C-terminal; For the JAK binding motifs, the similar PXP motif is shaded in
grey. Φ illustrate ant hydrophobic residue
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[127, 128]. Each group of receptors is known to prefer-
entially recruit a specific STAT for activation [129] and
each group therefore contains a specific subset of
phospho-tyrosine motifs. Hence, group 1 harbors the
STAT5 consensus motif, pYXXL [130], whereas the
group 2 harbors the STAT3 consensus motif pYXXQ
[131]. In addition to distinct down-stream signaling re-
lated SLiMs, many of the experimentally known SLiMs
are also related to endocytosis, trafficking and degrad-
ation. Some of these are frequent and are well-described
motifs experimentally, such as the dileucine-motifs (i.e.
[D/E] XXX [L/I[L/I]] and [D/E]XXLL) seen in LIFR
[132] and IL-2Rβ [133]), and the tyrosine-based motifs
(i.e. YXXϕ), promoting clathrin-dependent endocytosis
and internalization, first identified in the TPOR (YRRL)
and later in the G-CSFR [134, 135]. Additionally, phos-
phorylation dependent degrons (i.e. DSGXXS) [136–
138], promoting ubiquitin-dependent proteasomal deg-
radation are also well characterized in both GHR and
PRLR [136–138]. The motifs are summarized in Table 2.
For the longest ICD-isoforms of group 1, we subse-
quently predicted SLiMs and phosphorylation sites using
the Eukaryotic Linear Motifs server (ELM) [106] and the
iGPS [107], respectively (see methods), and mapped
these to the sequences, marking those already experi-
mentally confirmed (Fig. 3b). We made three important
observations. First, the predicted SLiMs as well as their
flanking regions are rich in amino acids that promote
extended structures, such as Pro, Val and Leu [139], in
accordance with the structures adapted in the bound
states [79, 140, 141], and the compositional analysis
made above. Second, it was evident that clusters of over-
lapping SLiMs are frequent and distributed across the
ICD sequences, interleaved with stretches depleted in
SLiMs (Fig. 3b). Clusters of overlapping SLiMs may be
scaffolding hot spots where multiple binding events can
take place in a controlled manner, largely determined by
binding competition, i.e. affinity, concentration and
PTMs. However, IDPs may also accommodate simultan-
eous binding of several partners and thereby orchestrate
signaling by bringing relevant proteins into close prox-
imity [142]. As evident from Table 2, similarities be-
tween the tyrosine-based motifs are pronounced.
Consequently, STAT and SOCS binding motifs may
overlap, but also with phosphatase binding sites, such as
e.g. for SHP2 [143–145], as well as with tyrosine-based
internalization motifs. Thus, regulation of signaling fate
by discrimination and availability via compressed motifs
appear widespread in C1CRs and is critically linked to
properties of disorder. Until recently, C1CR-regions with
overlapping motifs have exclusively been characterized
in the membrane distal regions. However, accumulating
evidence suggest that also the membrane proximal re-
gions contain SLiM-clusters. In GHR, the membrane
proximal ~ 60 residues region contains a LID with an
unknown function [82], a ubiquitin dependent degron
whereto the E3-ligase βTrCP docks and promote GHR
downregulation [136], as well as JAK2 [51] and Src kin-
ase (LYN) binding sites [48] (Fig. 3c). JAK2 and LYN are
the primary kinases in GHR signaling, controlling the
activation of JAK2/STAT5 and MAPK pathways, re-
spectively [48]. Both are known to be constitutively asso-
ciated with the receptor ICD [48, 146] and their relative
activation of pathways can be perturbed by mutations in
the ECD affecting TMD alignment [48]. However, the
molecular details of how the change in TMD alignment
is associated with pathway selectivity are still unknown,
but may be controlled by competitive binding of JAK2
and LYN and even further affected by membrane inter-
action. Similarly, GHR downregulation by βTrCP may
likewise be driven by competition in binding. Thus, this
region represents one of the essential composite SLiM-
clusters in GHR with hitherto unexplored implications
for the regulation of GHR signaling.
Typically, multiple binding events in IDPs are regu-
lated by phosphorylations and can be characterized as
binary on/off switches. However, accumulating evi-
dence have revealed that phosphorylations can generate
much more complex responses (reviewed in [147]), and
multisite phosphorylation can additionally generate
sensitive threshold responses as well as graded re-
sponses. The third important observation we made was
that in the group 1 C1CRs, several phosphorylation
sites were predicted, but only a small subset of these
were well-characterized experimentally. Hence, much
remains to be understood in terms of regulation and
the many modification sites open the possibility that
the C1CR-ICDs can have rheostat regulatory potential
[17]. In this way, successive phosphorylations may
additively increase (or decrease) binding affinity enab-
ling graded responses, or they may modulate the
conformational ensemble, with impact on signaling
output. Importantly, multisite phosphorylations, which
are functionally relevant for IDPs, remains to be addressed
in the C1CRs.
In summary, interactions by C1CR-ICDs are primarily
mediated by SLiMs, creating docking and modification
sites for several accessory signaling proteins. Further-
more, clusters of overlapping SLiMs dominate the
C1CR-ICDs, which together with the structural plasticity
provided by the disorder properties, impart a unique
condensed and versatile signaling scaffold, enabling es-
tablishment of large interactomes, whose content is con-
trolled by the available pool and concentrations of
interaction partners as well as PTMs. The spatio-
temporal orchestration of signaling therefore rely on
availability of the binding partner, affinities and kinetics
and altogether eventually determine signaling fate.
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Network rewiring by isoforms
In order to investigate different C1CR-ICD isoforms at
the molecular level, we took two approaches. First, we
compared a long and a short isoform experimentally,
using the PRLR as model, and second, we predicted and
compared the presence of SLiMs for those C1CRs,
which have longer isoforms that differ in the ICD se-
quence (i.e. having isoforms of unique sequence, not just
truncations).
First, we expressed and biophysically characterized
PRLR-SF1b (residues 259–288) and compared it to
PRLR-LF-ICD. PRLR-SF1b-ICD is much shorter (32 ver-
sus 386 residues) and differs only in the last three C-
terminal residues, where K286, G287 and K288 of
PRLR-LF-ICD are substituted by V286, T287, and P288
(P288 is the new C-terminus). Apart from the loss of
multiple interaction sites by being shorter, including the
loss of Box2, the chemical change from net positively
charged to uncharged with more hydrophobic residues
may influence the structural preferences as well as the
interactome, especially membrane binding. From de-
tailed NMR analyses, the PRLR-SF1b-ICD maintained
structural disorder and dynamics (SI Fig. 5a-c), but tran-
sient helix 1, observed in the PRLR-LF-ICD, was elimi-
nated in the PRLR-SF1b-ICD as seen by smaller
secondary chemical shifts (SCSs) of Cα nuclei (Fig. 4a
and SI Fig. 5c-d). This demonstrates that two isoforms
differing only in three residues, may have different struc-
tural propensities (Fig. 4a). Functionally, however, and
despite structural and chemical changes, membrane
interaction using small-unilamellar vesicles of POPC:
POPS (3:1) as membrane mimetics, previously observed
for PRLR-LF-ICD [82], was preserved in PRLR-SF1b-
ICD with loss of NMR signal intensities and chemical
shift perturbations (Fig. 4b,c). Box1 was previously sug-
gested to interact with cyclophilin A (CypA) [149], and
Box1 proline cis/trans isomerization claimed important
for this interaction [84]. However, form NMR chemical
shift analyses (SI Table S1), Pro cis/trans isomerization
appeared not to be dominant in the free state of neither
isoforms, and accordingly none of them interacted with
CypA (SI Fig. 5f-i). Thus, despite sequence and structure
differences between the two isoforms, functionality was
maintained in the short isoform. In this case, shortening
of the ICD by removing 90% of it, including numerous
SLiMs and phosphorylation sites, as well as docking sites
for STAT and SOCS, in this case only resulted in a
major reduction in the interactome.
Shorter isoforms as described for PRLR exist for 9 of
the C1CRs. However, many ICD isoforms have longer
regions of unique sequence, which differ from the ca-
nonical isoform. Thus, to explore if these longer ICD
isoforms may have gained new interactions sites, we pre-
dicted which common SLiMs were gained or lost,
disregarding potential phosphorylation sites and
receptor-unique SLiMs (Table S2). The unique se-
quences were found to carry distinct SLiMs. In the case
of group 1, a 14–3-3 binding SLiM has previously been
identified in PRLR isoform 1 [148]; a SLiM originally
discovered active in cytokine receptors in the IL-9R
[150]. However, predictions suggested the presence of a
different 14–3-3 motif, just six residues C-terminal to
the experimentally described site (Fig. 4d, SI Table S2).
Compared to the PRLR-LF-ICD, the short forms did not
possess the STAT-docking sites or the 14–3-3 binding
SLiM. Instead, a different 14–3-3 binding SLiM each
with different sequence properties was predicted in the
unique sequences (SF1a and SF1c) (Fig. 4d). For TPOR,
isoform 2 had two 14–3-3 SLiMs, which were absent in
isoform 1, while for the GHR and EPOR, which do not
have any known 14–3-3 binding SLiMs, the isoforms
with unique sequences (isoform 2 and 3 of GHR and
isoform T of EPOR) were much shorter, and without
any predictable common or different SLiMs. Thus, for
PRLR, the preservation of the 14–3-3 SLiM despite
changes in sequence suggest a key regulatory function,
one of which may be to attenuate receptor signaling as
suggested [148]. Relevantly, the LFs of EPOR, GHR and
PRLR all had a phosphorylation dependent degron,
interacting with the SkpSCF-betaTrCP1 complex or the
Skp1_Cullin-Fbox, leading to ubiquitylation and degrad-
ation, as shown experimentally for PRLR and GHR,
where it negatively regulates receptor stability [136, 137].
These were not identified in any of the shorter isoforms,
which also have been seen to be stabilized on the mem-
brane [151]; a possible result of the lack of associated
proliferative signaling and hence lack of need for imme-
diate down regulation.
For other receptors, e.g. the IL-31Rα (GLMR) and
LEPR isoforms, we found that unique sequences intro-
duced PDZ binding SLiMs at the new C-termini (Fig.
4e). Furthermore, when the PDZ motif is present, each
IL-31Rα (GLMR) receptor isoform had a unique PDZ-
binding SLiM (expect for isoforms 3 and 5, which are
identical in their ICDs), allocating the isoforms to inter-
act with different classes (Class 1,2 and 3) of PDZ do-
mains (Fig. 4e) [152, 153]. The same was true for the
LEPR, where each isoform has a unique PDZ binding
SLiM (Fig. 4f). In fact, the introduction of a PDZ SLiM
in the C-terminus in one isoform was observed for sev-
eral receptors including G-CSFR, IL-7Rα, IL-9Rα, and
GM-CSFRα (Table S2). Why these isoforms need PDZ
binding motifs is not clear, but several scaffolding pro-
teins with specialized subcellular localization and tissue
specificity exist, known to contain multiple PDZ do-
mains by which they orchestrate supramolecular com-
plexes. Binding of the IL-5Rα-ICD to a PDZ domain
from syntenin (Fig. 1 b) [81] supports the involvement
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Fig. 4 Network rewiring by disorder. Top; Comparison of a long and short isoform of PRLR. a Structural propensities of the PRLR-LF-ICD
compared to PRLR-SF1b-ICD illustrated by differences in NMR secondary chemical shifts (SCSs) of Cα. Red coloring indicates lower Cα SCSs in
PRLR-SF1b-ICD compared to PRLR-LF-ICD, and hence less helicity. b NMR chemical shift perturbations upon addition of POPC/POPS SUVs to
PRLR-SF1b-ICD and c intensity ratios of PRLR-SF1b-ICD in the absence and the presence of POPC/POPS SUVs. Red circles highlight prolines and/or
unassigned residues and shaded areas loss of NMR signal upon addition. Bottom; Predicted and selected binding SLiMs in the isoforms of d
PRLR, e IL-31Rα (GLMR), and f LEPR (OBR). Introduction of potential new binding SLiMs in the unique sequences are indicated by the sequence of
the SLiM, and the presence of SLiMs in the LF of the isoforms is indicated with a “+”. When a SLiM is not present, this is indicated by a “-”. The
length of the ICD is indicated by the scale bars on top, and red lines illustrate the length of the unique sequence. “*” indicates a different SLiM
compared to the binding site identified by mutations in [148]. Alternative names for the isoforms are given in the second row. For other C1CR
isoforms, see Table S2
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of further scaffolding proteins for formation of larger
signaling complexes. PDZ containing protein may be of
relevance to the C1CRs and could engage proteins from
the NHERF and PSD-95 families [154], which also scaf-
fold kinases as Fyn [155]. Alternatively, E3-ligases be-
longing to the MARCHs family coordinate binding via
PDZ domains and are relevant for ubiquitylation of pro-
teins in the intracellular membranes [156]. However, be-
sides the complex between the IL-5Rα-ICD and the PDZ
domain from syntenin, complexes of C1CRs with PDZ
domains remain to be experimentally explored. Finally,
for all receptors with isoforms, the longest isoform, ex-
cept for GM-SCFRα, carries the interaction with STATs,
either STAT5 or STAT3 or both, but, additionally also
carry a binding motif for TNF receptor-associated factor
(TRAF)-2 or TRAF-6, none of which are found in other,
shorter isoforms. In a few cases, the STAT and/or TRAF
motifs are maintained in the second longest isoform,
and sometimes a shift between STAT5 and STAT3 or
between TRAF-2 and TRAF-6 occurs.
Thus, for the C1CRs, the disorder predictions and ex-
perimental characterization of selected representatives
have suggested that the isoforms maintain structural dis-
order, and their presence suggests several mechanisms
by which disorder orchestrates signaling. The first is the
complete removal of a large part of the ICD, eliminating
SLiMs important for STAT activation, TRAF interaction
and downregulation by degradation via degron activa-
tion. In this way the shorter isoforms act as negative reg-
ulators, or decoy receptors, of signaling, as seen for the
short forms of the PRLR and GHR [62, 151]. However,
these isoforms still maintain binding capacity as seen
from for membrane binding of PRLR-SF1b above. The
second mechanism by which isoforms orchestrate signal-
ing is via rewiring of the interactome to access com-
pletely new networks, exemplified by the addition and
removal of binding sites for e.g. 14–3-3 proteins and
PDZ domains. This allows for different signaling profiles
dependent on expression profiles of the C1CR-ICD iso-
forms. However, more studies into network rewiring of
the C1CRs are warranted, and the analysis made here
merely provides a starting point.
The conformational ensembles of C1CR-ICDs
IDPs are functional without taking on a single, well-
defined tertiary structure. Yet, they cannot adequately be
described as simple statistical coil chains equally popu-
lating all possible conformations allowed by their back-
bone torsion angles. Instead, IDPs display varying
degrees of compaction and elongations, and contain
transient, short- and long-range structural organizations.
Hence, the disorder of the C1CR-ICDs not only infer
flexibility and high accessibility of binding sites, but cer-
tain chain dimensions and spatial organizations may
influence the organization of the signaling complexes
and orchestration of protein interactions, and in the end,
signaling outcome. Currently, the conformation and di-
mensions of IDPs cannot be quantitatively predicted
from sequence [157, 158]. Nonetheless, the balance be-
tween chain-chain and chain-solvent interactions that
determines the conformational preference is related to
specific sequence features that influence the conform-
ational ensembles in predictable ways [101, 157, 159,
160]. One set of these relates to global compositional se-
quence features (i.e. parameters that are independent on
the sequence order), and the fraction of charged residues
and the net charge per residue are particularly important
[159, 161]. In addition, features relating to sequence pat-
terning, especially the patterning of oppositely charged
residues and expansion promoting residues, influence
compaction [158]. However, the current difficulties in
consistently predicting the conformational ensemble of
all IDPs reflects that some of these behaviors are
encoded in sequence features yet to be unraveled.
IDPs have been classified into five compositional
groups in a diagram of states [161] based on their frac-
tion of positively charged residues (f+) and fraction of
negatively charged residues (f−). These two global pa-
rameters are combined into two measures underlying a
diagram of states: the fraction of charged residues
(FCR = f+ + f−) and the net charge per residue (NCPR =
f+ − f−). An explanation of the relation between these pa-
rameters and the properties of the chain is given in the
supplemental data. Of 879 IDRs longer than 15 residues
found in DisProt, CIDER [101] classified 40% as belong-
ing to R1, 35% to R2, 22% to R3, and 3% to either R4 or
R5 [157]. For each C1CR-ICD, the sequence of isoform
1 was submitted to CIDER [101], except for LEPR and
G-CSFR, for which isoform B and 3, respectively, were
selected as these were the longest isoforms (see Table 1).
For GM-SCFRα, both isoform 1 and 2 were analyzed be-
cause they differed in more than 50% of their C-terminal
sequences (see Table 1). The C1CR-ICDs generally fell
close to the boundary between R1 and R2, with most be-
longing to R1 (61%) (Fig. 2a), suggesting a preference for
compact, but still dynamic, heterogenous conformational
ensembles [157]. Nonetheless, in particular for sequences
belonging to R2, their overall charge neutrality means that
their conformational preference cannot be predicted from
global composition alone [157, 159]. Furthermore, it
should be noted that the boundary between R1 and R2
has been determined ad hoc, and has been suggested to be
positioned at lower FCR for longer sequences [157, 159].
Furthermore, for ICDs > 100 residues or with a high pro-
line fraction
(> 0.15), no qualitative prediction of the conformation can
be made for sequences of R1, as these tend to have more
extended conformations than their scores predict.
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Since almost all the C1CR-ICDs are long IDPs of R1
and R2, the conformational preferences cannot be pre-
dicted from global composition alone but may also be
influenced by e.g. sequence patterning. Particular the
patterning, or mixing, of oppositely charged residues is
important, as well as expansion driving- and aromatic
residues. The parameter κ reports on how well positively
and negatively charged residues are segregated across
the sequence and is normalized between 0 and 1, with κ
close to zero representing sequences with evenly distrib-
uted charges, while sequences with κ close to 1 have
highly segregated charges. It has been shown that as κ
approaches 1, the conformational ensemble becomes
more compact [161]. However, since κ is calculated by
normalizing to the most segregated sequence within the
given composition, a specific κ value will not have the
same meaning for two sequences with different FCR and
|NCPR| values. Furthermore, for long IDRs, such as
most of the C1CR-ICDs, κ is calculated only within a
window of 5 and 6 residues, ignoring long-range effects.
κ is most informative for sequences with an FCR above
0.25 and NCPR between − 0.1 and + 0.1, for which a κ
below 0.12 is considered low and a κ above 0.25 is high.
Especially for polyampholytic sequences with an FCR be-
yond 0.4, charge patterning is predicted to have a major
impact on the conformation [160]. There is one such ex-
ample, namely the GM-CSFRα, which has an FCR of
0.41, an NCPR of − 0.07 and a κ of 0.25, suggesting
chain compaction.
The position of the far majority (94%) of the C1CR-
ICDs in R1 and R2 is a consequence of their low net
charges. Their FCR values are in the mediocre range of
0.1 < FCR < 0.3 [160], while at the same time, their
NCPR is close to 0, demonstrating that they are near-
symmetrical polyampholytes. For the C1CR groups with
long ICDs (1, 2 and 4), the group average FCRs (0.21;
0.23; 0.19) and NCPRs (− 0.06; − 0.06; − 0.05) are re-
markably similar, suggesting that charge properties are a
conserved trait. The similarity of these parameters also
allows us to compare their κ values more directly, going
from a group average of 0.20 for group 1, 0.18 for group 2
to 0.22 for group 4. This is consistent with the IDDomain-
Spotter analysis presented earlier (Fig. 2c). Here we found
that almost all of the C1CR-ICDs harbored a PD immedi-
ately following their TMD, succeeded by an ND, and with
net charge neutral regions for the remainder of the chain.
Together, this suggest that the influence of the global
charges and the charge patterning on the conformational
ensembles are consistent throughout group 1, 2 and 4, ex-
cept for IL-31Rβ (OSMR) (group 2) and IL-4Rα (group 4).
As mentioned, the shorter ICDs of group 3 and 5 result in
somewhat different global charge properties.
The Ω parameter both describes the patterning of the
charged residues as well as of proline. Like for κ, Ω is
normalized between 0 and 1, with Ω close to zero repre-
senting sequences with evenly distributed charges and
prolines, while sequences with Ω close to 1 have highly
segregated charges and prolines [162]. It has been shown
that when Ω approaches 1, the preference for expanded
conformations increases [162]. A high fraction of Pro (>
~ 15%) may cause more expanded conformations as Pro
prefers to be solvated and promotes stiffness. Five of the
C1CR-ICDs had a high fraction of Pro (15–19%): IL-
27R, IL-6Rα, IL-11Rα, βc, IL-13Rα2 (Fig. 5a, top). The
amino acid fraction and IDDomainSpotter analysis (Fig.
2) revealed that the Pros are unusually abundant in the
C1CR-ICDs and close to equally distributed. From the
CIDER analysis we found that Ω, like κ, is similar for
many of the C1CR-ICDs, but is lower for the shorter se-
quences (Fig. 5a). This could simply be a consequence of
the Pro-rich Box1 sequences, leading to relatively higher
proline scores in the shorter sequences.
To summarize, the theoretical analysis of the C1CR-ICD
sequence parameters known to influence compaction sug-
gest that many of them may be similarly biased towards a
specific degree of extension or compaction of their conform-
ational ensembles, but that this degree cannot be predicted
from sequence. Hence, to determine this bias, we experimen-
tally investigated the degree of compaction and its respon-
siveness to salt by SAXS using two long, representative
C1CR-ICDs, namely that of PRLR-LF-ICD (Fig. 5b,c) and
GHR-LF-ICD (SI Fig. S6). The SAXS profiles of the PRLR-
LF-ICD were consistent with those expected for fully disor-
dered proteins, and was fitted to an Rg of 57.3 ± 1.4 Å in 20
mM phosphate buffer. The predicted Rg of the PRLR-LF-
ICD for a fully random coil state is, according to Kohn et al.
[98], 65Å, suggesting that the PRLR-LF-ICD populate a
slightly compacted ensemble. The pair distance distribution
function (P(r)), which is a histogram of distance distributions
within the protein, peaks at ~ 45Å and has a Dmax of ~ 200
Å. Increasing the concentration of salt to 300mM did not
significantly affect the fitted Rg nor the P(r) distribution (Fig.
5b,c), suggesting that the global degree of compaction of
PRLR-ICD is not sensitive to salt, as otherwise often ob-
served for more charged IDPs [163], perhaps related to the
high content of Pro and branched amino acids. The same
trends were observed from SAXS on the GHR-LF-ICD, hav-
ing a similarly slightly compacted ensemble that was insensi-
tive to salt (SI Fig. S6). Hence, the ICDs across the C1CR
family having similar global charge properties and patterning
(Fig. 5a), may populate similarly compacted ensembles as
also indicated from the Ω scores (0.15–0.35), although this
remains to be experimentally more broadly verified.
Versatile and controlled orchestration of signaling by
unique structural disorder in C1CRs
It is remarkable that the entire family of C1CRs, differ-
entiating into > 50 isoforms, are all predicted to be
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disordered in their entire ICD sequence. Nonetheless,
the disordered ICDs are critically understudied, leaving
us with a naive and too simplistic schematic view of the
ICDs as passive strings of varying lengths with kinases
constitutively attached. In the present paper we have
highlighted the properties linked to disorder responsible
for controlling the diverse signaling by C1CRs (Table 2)
and asked: Why has disorder been selected for governing
intracellular C1CR signaling? Their complete disordered
nature stands in contrast to the majority of other types
of single-pass transmembrane receptors such as the re-
ceptor tyrosine kinases, where intracellular signaling is
mainly governed by intrinsic kinase activity. We have
here shown that the long disordered ICDs of C1CRs are
brimming with clusters of multifunctional SLiMs
throughout their length, suggesting that one explanation
is the signaling versatility and scaffolding capacity of this
type of ICD. Furthermore, we have outlined that
overlapping SLiMs are prevalent in the C1CR-ICDs,
hinting that the disordered ICDs further allow for com-
plex regulation of diverse signaling through competition
and regulation of interactions with a plethora of different
binding partners through multispecificity. Thereby, acti-
vation becomes dependent on the coupled equilibria and
kinetics of two (or more) binding events. Indeed, the
ability of a distinct region in the disordered ICD to bind
to many different proteins is facilitated by structural
adaptation and folding-upon-binding [164, 165]. Add-
itionally, the C1CR-ICDs are hot spots for multiple
phosphorylation events of which only a few are well-
characterized as binary on-off switches. This directly –
or indirectly – affect affinities and additionally expands
the number of states accessible by the chain at any time.
We have further suggested that an additional layer to
this regulation is added by the existence of different
C1CR-ICD isoforms, in which entire groups of SLiMs
Fig. 5 Conformational properties of C1CR-ICDs. a Plot of conformational parameters provided by CIDER analyses of the longest isoforms of the
C1CR-ICDs. For GM-SCFRα, both isoform 1 and 2 were analyzed as they differed > 50%. Each receptor group is highlighted with different colors; 1
– blue, 2 – green, 3 -yellow, 4 – red, and 5 - purple. When sequences have a Pro warning, i.e. a Pro fraction > 0.15, the ICD is highlighted with a P
on top. The numbers at the top are the compositional region assigned by CIDER. # residues are the numbers of residues in the ICD, FCR is the
fraction of charged residues (FCR = f+ + f−), NCPR is the net charge per residue (NCPR = f+ − f−), κ is a measure of the charge mixing across the
sequence (normalized between 0 and 1) and Ω additionally takes Pro mixing into account (normalized between 0 and 1). The dotted lines at 0.4,
0.3, and 0.1 in the FCR plot represent the borders for very highly charged (above), highly charged (above) and highly depleted (lower) in charges,
respectively [160]. The area between the dotted lines at 0.1 and − 0.1 in the NCPR plot represents the range occupied by 70% of human IDPs
[160]. b Experimental SAXS data (spheres) and Gaussian random coil model fit (lines) for PRLR-LF-ICD at different concentrations of NaCl (see
color key), with the residuals from the fit shown below in units of standard deviations. c Pair distance distribution functions for the PRLR-LF-ICD
SAXS data. The color coding is the same as in b)
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can be eliminated and new ones added, a feature that is
much easier for IDPs to successfully obtain during evo-
lution compared to folded proteins. By controlled ex-
pression of the isoforms, a complete rewiring of the
interaction network can be done. Hence, the full disor-
dered nature of the C1CR-ICDs allows for a fascinatingly
versatile and complex interaction hub.
Can such signal complexity be facilitated through a
simple string with kinases attached? Our sequence ana-
lysis and experimental studies have revealed biases in
the C1CR-ICDs that differentiate them from being sim-
ple statistical coils. They have conserved distinct com-
positional biases that differentiate them from other
IDPs; biases that are distributed throughout their chains,
including the presence of disordered domains of specific
physiochemical properties. This suggests that these com-
positional biases are representing shared functionalities
yet to be characterized. Our experimental SAXS data on
the long ICDs of the archetypical receptors GHR and
PRLR revealed that they are slightly more compacted
than expected for a fully random coil (~ 57 Å versus 65
Å for PRLR-LF-ICD). This indeed suggests an inherent
conformational bias based on the conservation of certain
sequence properties maintained across the family. Im-
portantly, however, it should be kept in mind that in the
cell, the C1CR-ICDs are most likely never completely
void of interactions at any point. Previous characteriza-
tions of PRLR-LF-ICD and GHR-LF-ICD have revealed
the presence of LIDs, further suggesting distinct
organizational features at the membrane interface where
also many kinases are tethered. Additionally, we found
that the same sets of SLiMs are placed differently in the
C1CR-ICDs with variable distances, which may provide
an additional tuning of the signaling outcome, both via
the length of their disordered spacers as well as the
properties of these [166]. Thus, SLiM organization
within the chain may imprint different affinities in differ-
ent complexes despite their exploitation of identical
SLiMs, providing an additional layer of the spatio-
temporal orchestration of signaling. In fact, is it possible
that disordered cytoplasmic domains generally can be
classified by their collection of SLiMs, providing specific
SLiM catalogues of disordered membranes proteins, but
such decomposition will require a much broader analysis
across many different protein families.
Conclusion
In conclusion, we suggest that the C1CR-ICDs are far
from simple strings with constitutively bound kinases.
Rather, they carry both organizational and operational
features left uncovered in their disorder, but of key im-
portance for understanding orchestration of signaling.
How these features operate in the higher-order oligo-
mers of the C1CRs, bringing ICDs from several chains
in close proximity, increases the dimension of future
studies. For example, the mere volume taken up by more
chains may allow them to generate higher order ensem-
bles of specific properties. In such disordered reaction
chambers, lower affinity interactions may be boosted
and even shared between chains adding features, mecha-
nisms and complexities to regulations, also yet to be dis-
covered. Taken together, it is evident that the
understanding of the fascinating ability of these long,
completely disordered chains to orchestrate complex sig-
naling pathways is still in its infancy.
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